Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Severe hypoglycemia and risks of vascular events and death.

Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S; ADVANCE Collaborative Group.

N Engl J Med. 2010 Oct 7;363(15):1410-8. doi: 10.1056/NEJMoa1003795.

2.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F.

N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.

3.

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, Macmahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M; ADVANCE Collaborative Group.

Diabetologia. 2009 Nov;52(11):2328-36. doi: 10.1007/s00125-009-1484-7. Epub 2009 Aug 18.

PMID:
19688336
4.

Hypoglycemia as a driver of cardiovascular risk in diabetes.

Moheet A, Seaquist ER.

Curr Atheroscler Rep. 2013 Sep;15(9):351. doi: 10.1007/s11883-013-0351-7. Review.

5.

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.

Khalangot M, Tronko M, Kravchenko V, Kovtun V.

Diabetes Res Clin Pract. 2009 Dec;86(3):247-53. doi: 10.1016/j.diabres.2009.09.008. Epub 2009 Sep 30.

PMID:
19796836
6.

Systematic review: glucose control and cardiovascular disease in type 2 diabetes.

Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J.

Ann Intern Med. 2009 Sep 15;151(6):394-403. Epub 2009 Jul 20. Review.

PMID:
19620144
7.

Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.

Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, Houweling ST, Bilo HJ, Kleefstra N.

PLoS One. 2014 Feb 12;9(2):e82880. doi: 10.1371/journal.pone.0082880. eCollection 2014. Review.

9.

Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes.

Zhao Y, Campbell CR, Fonseca V, Shi L.

Diabetes Care. 2012 May;35(5):1126-32. doi: 10.2337/dc11-2048. Epub 2012 Mar 19.

10.

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.

Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C.

Circulation. 2008 Apr 15;117(15):1945-54. doi: 10.1161/CIRCULATIONAHA.107.720847. Epub 2008 Mar 31.

11.

ADVANCE: action in diabetes and vascular disease.

Patel A, Chalmers J, Poulter N.

J Hum Hypertens. 2005 Jun;19 Suppl 1:S27-32. Review.

PMID:
16075030
12.

Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough?

Triplitt C.

Consult Pharm. 2010 Jun;25 Suppl B:19-27.

PMID:
20726379
13.

Intensive glycemic control and cardiovascular disease: an update.

Brown A, Reynolds LR, Bruemmer D.

Nat Rev Cardiol. 2010 Jul;7(7):369-75. doi: 10.1038/nrcardio.2010.35. Epub 2010 Apr 20. Review.

PMID:
20404853
14.

Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.

Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, Wang KQ, Zou YZ, Ge JB.

Ann Med. 2010 May 6;42(4):305-15. doi: 10.3109/07853891003796752.

PMID:
20429797
15.

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.

Huang ES, Meigs JB, Singer DE.

Am J Med. 2001 Dec 1;111(8):633-42.

PMID:
11755507
16.

[Hypoglycemia and cardiovascular risk].

Avogaro A.

G Ital Cardiol (Rome). 2014 Dec;15(12 Suppl 2):4S-12S. doi: 10.1714/1762.19110. Italian.

PMID:
25623545
17.

Does intensive glycemic control improve cardiovascular outcomes?

Pendergrass M.

Nat Clin Pract Endocrinol Metab. 2008 Oct;4(10):529. doi: 10.1038/ncpendmet0953. No abstract available.

PMID:
18806805
18.

Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes.

Brown SH, Abdelhafiz AH.

Postgrad Med. 2009 Sep;121(5):31-41. doi: 10.3810/pgm.2009.09.2050. Review.

PMID:
19820272
19.

[Glycemic control and cardiovascular diseases in type 2 diabetes].

Madsbad S.

Ugeskr Laeger. 2008 Nov 3;170(45):3634. Danish. No abstract available.

PMID:
18986612
20.

Diabetes. Paradoxical effects of tightly controlled blood sugar.

Taubes G.

Science. 2008 Oct 17;322(5900):365-7. doi: 10.1126/science.322.5900.365. No abstract available.

PMID:
18927369
Items per page

Supplemental Content

Write to the Help Desk